Ticker Details
Altimmune, Inc. Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases.
IPO Date:	May 22, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$548.51M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.30 | 4.08%
Avg Daily Range (30 D):	$0.18 | 3.69%
Avg Daily Range (90 D):	$0.15 | 3.17%

Institutional Daily Volume
Avg Daily Volume:	1.92M
Avg Daily Volume (30 D):	4.18M
Avg Daily Volume (90 D):	3.92M

Trade Size
Avg Trade Size (Sh.):	162
Avg Trade Size (Sh.) (30 D):	197
Avg Trade Size (Sh.) (90 D):	197

Institutional Trades
Total Institutional Trades:	1,562
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$1.37M
Avg Institutional Trade (90 D):	$1.28M
Avg Institutional Trade Volume:	.2M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.91M
Avg Closing Trade (30 D):	$1.36M
Avg Closing Trade (90 D):	$1.3M
Avg Closing Volume:	229.83K

News

Jan 29, 2026 @ 10:54 PM Altimmune Announces Closing of $75 Million Registe... Source: Globe Newswire

Jan 29, 2026 @ 10:54 PM Altimmune Announces Closing of $75 Million Registe... Source: Na

Jan 29, 2026 @ 6:31 PM Longevity Biotech Stocks Surge as $27 Trillion Hea... Source: Prnewswire

Jan 28, 2026 @ 2:25 AM Altimmune Announces Pricing of $75 Million Registe... Source: Na

Oct 31, 2025 @ 4:00 PM Biodefense Market to Attain USD 32.87 Billion by 2... Source: Towards Healthcare

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$-.21	$-.27	$-.26
Diluted EPS	$-.21	$-.27	$-.26
Revenue	$.01M	$.01M	$.01M
Gross Profit
Net Income / Loss	$-19.01M	$-22.15M	$-19.58M
Operating Income / Loss	$-20.86M	$-22.92M	$-21.82M
Cost of Revenue
Net Cash Flow	$-121.87M	$134M	$12.18M
PE Ratio

Splits
Sep 14, 2018	1:30
May 05, 2017	1:10
May 04, 2017	1:10
Jul 25, 2007	1:50